| Reference: | 1. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: The 2008 Revision. http://esa.un.org/unpp, Saturday, September 25, 2010.
2. Bill Mitchell, The US should have universal public health care. http://bilbo.economicoutlook.net/blog/?p=8909 Sunday, Oct 3,2010.
3. WHO (May 2009). "World Health Statistics 2009" http://www.who.int/whosis/whostat/2009/en/index.html, Sunday, Oct 3, 2010
4. Institute for research and information in health economics. OECD Health Data 2010 – Frequently Requested Data. http://www.irdes.fr/EcoSante/DownLoad/OECDHealthData_FrequentlyRequestedData.xls, Monday, Oct 4, 2010.
5. Claus Moldrup No Cure, No Pay. BMJ 2005;330:1262-4.
6. 全民健康保險藥品論質計酬計畫實施要點(草案）. 全民健康保險藥事小組第8屆第16次會議紀錄附件5. http://www.nhi.gov.tw/webdata/AttachFiles/Attach_15849_2_第8屆第16次會議紀錄(990728).pdf, Saturday, Oct 9, 2010.
7. 全民健康保險藥價基準(民國99年9月24日修正） http://dohlaw.doh.gov.tw/Chi/FLAW/FLAWDAT0202.asp?lsid=FL037963, Feb 12, 2011.
8. Ferris, J. & S. Tang, The New Institutionalism and Public Administration: An Overview. Journal of Public Administration: Research and Theory 1993;3(1):4-10.
9. North, D.C. Economic Performance through Time. American Economic Review 1994;84:359-68
10. Davis, L. and North, D.C. 1971. Institutional Change and American Economic Growth. Cambridge: Cambridge University Press.
11. Williamson, O.E. 1985. The Economic Institutions of Capitalism. New York: The Free Press.
12. Commons, J.R. 1934. Institutional Economics. Madison: University of Wisconsin Press.
13. Williamson, O.E. Transaction-Cost Economics: The Governance of Contractual Relations. Journal of Law and Economics 1979;22:233-61.
14. Coase, R.H. The Nature of the Firm. Economica 1937;4:386-405.
15. Arrow, K.J. 1969, The Organization of Economic Activity: Issues Pertinent to the Choice of Market versus Non-Market Allocation. The Analysis and Evaluation of Puclic Expenditures: The PBB-System, Joint Economic Committee, 91st Cong., 1st sess., Vol. 1. Washington, D.C.: Government Printing Office.
16. Scherer, F.M. 1987. Selling Costs. In Eatwell, J., Milgate, M. and Newman, P.(Eds.) The New Palgrave: A Dictionary of Economics, 4:300-301. London: Macmillan.
17. 吳思華，策略九說—策略思考的本質，二版，台北：臉譜文化1996。
18.Burt, R.S. 1992. Structural Holes: The Social Structure of Competition. Cambridge: Harvard University Press.
19.Miller, J.G. and Vollmann T.E. The Hidden Factory. Harvard Business Review 1985;55(5):142-50.
20. Levi, M. 1988. Of Rule and Revenue. Berkeley: University of California Press.
21. Ouchi, W. G. A Conceptual Framework for the Design of Organizational Control Mechanisms. Management Science 1979;25(9):833-848.
22. Rindfleisch, A. and J. Heide, Transaction Cost Analysis: Past, Present, and Future Applications. Journal of Marketing 1997;61(4):30-54
23. Chiles TH. Mcmackin JF. Integrating Vairable Risk Preferences, Trust and Transaction Cost Economics. The Academy of Management Review 1996;21(1) 73-99.
24. Shelanski, Howard A., and Peter G. Klein, "Empirical Research in Transaction Cost Economics: A Review and Assessment," Journal of Law, Economics and Organization11, no. 2 (October 1995): 335-61. Reprinted in Glenn R. Carroll and David J. Teece, eds., Firms, Markets, and Hierarchies: The Transaction Cost Perspective (New York: Oxford University Press, 1999), pp. 89-118.
25. Klein, B. Self-Enforcing Contacts. Journal of Institutional and Theoretical Economics 1985;141:594-600.
26. Weber, M. 1968. Economy and Society: An Outline of Interpretative Sociology. Edited by Roth G. and Wittich C. Berkeley: University of California Press.
27. Brousseau, E. and Glachant, JM. 2002. The Economics of Contracts: Theories and Applications Cambridge: Cambridge University Press.
28. Jensen, M. C., and Meckling W. H., Theory of the Firm: Managerial Behavior, Agency Costs and Ownership Structure. Journal of Financial Economics 1976;3:305-60.
29. Grossman, Sanford J & Hart, Oliver D, "The Costs and Benefits of Ownership: A Theory of Vertical and Lateral Integration," Journal of Political Economy. 1986;94(4):691-719.
30. Tirole, J., Incomplete Contracts: Where Do We Stand? Econometrica. 1999;67(4):741-781.
31. Hart, O. and Moore, J. Property Rights and the Nature of the Firm. Journal of Political Economy, 1990;98(4):1119-1158.
32. Foss, K. and Foss, NJ. Theoretical isolation in contract theory: suppressing margins and entrepreneurship. Journal of Economic Methodology. 2000;7(3):313-339.
33. Baker, G., Gibbons R. and Murphy KJ., Relational Contracts and the Theory of the Firm, The Quarterly journal of economics, 2002;117(1):39-84.
34. Chen Y.M. Promises, trust, and contracts. Journal of Law Economics and Organization. 2000;16(1):209 232.
35. The Pharmaceutical Price Regulation Scheme 2009. Department of Health and the Association of the British Pharmaceutical Industry, December 2008. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091825 Monday, May 23, 2011.
36. Alberta Pharmaceutical Strategy Phase Two-Brand Name Drugs (Fact Sheet). Alberta Health and Wellness, October 2009. http://www.health.alberta.ca/documents/Pharma-Strategy-2-Brand-Drugs.pdf Monday, May 23, 2011
37. Guidelines for Deeds of Agreement for the Pharmaceutical Benefits Scheme (Version 1.3). Department of Health and Ageing, 2009. http://www.pbs.gov.au/pbs/pdf-viewer?pdf=%2Findustry%2Flisting%2Felements%2Fdeeds-agreement%2FGuidelines_for_Deeds_of_Agreement.pdf Monday, May 23, 2011.
38. Carlson JJ, Garrison LP, Sullivan SD. Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals. J Manag Care Pharm 2009; 15:683-7.
39. Garber AM, McClellan MB. Satisfaction Guaranteed “Payment by Results” for Biologic Agents. N Engl J Med 2007;357:1575-7.
40. Ehreth J, Williams D. European Pharmaceutical Pricing and Reimbursement conference. Expert Review of Pharmacoeconomics & Outcomes Research 2009;9:37-9
41. Datamonitor Healthcare. Pricing and Reimbursement: Innovative Risk-Sharing Strategies. July, 2009
42. Trueman P, Grainger DL, Downs KE. Coverage with Evidence Development: Applications and Issues. International Journal of Technology Assessment in Health Care 2010;26:79-85.
43. Sullivan SD, Garrison LP, Carlson JJ, et al. Performance-Based Risk-Sharing Reimbursement Agreements for New Medical Products (Executive Summary). In: ISPOR 11th Annual European Congress: Risk-sharing agreements panel. Athens: Pharmaceutical Outcomes Research and Policy Program, University of Washington; 2008.
44. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking Payment to Health Outcomes: A Taxonomy and Examination of Performance-based Reimbursement Schemes between Healthcare Payers and Manufacturers. Health Policy 2010;96:179-90.
45. Akerlof GA. The Market for "Lemons": Quality Uncertainty and the Market Mechanism. The Quarterly Journal of Economics 1970;84(3):488-500.
46. Rebecca A. Williams et al. The Psychosocial Impact of Macular Degeneration. Arch Ophthalmol. 1998;116:514-520.
47. Brown GC etal. Difference between ophthalmologists` and patients` perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol. 2000;35(3):127-33.
48. Philip J. Rosenfeld et al. for the MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 2006;355:1419-31.
49. David M. Brown et al. for the ANCHOR Study Group. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. N Engl J Med 2006;355:1432-44.
50. National Institute for Health and Clinical Excellence, NICE technology appraisal guidance 155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. Aug 2008. http://www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf
51. National Institute for Health and Clinical Excellence, Audit Support. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. Sep 2008. http://www.nice.org.uk/nicemedia/live/12057/41926/41926.doc
52. Department of Health and Ageing. About Pharmaceutical Benefits Scheme http://www.pbs.gov.au/info/about-the-pbs
53. Department of Health and Ageing. Sensory organs > Ophthalmologicals > Ocular vascular disorder agents http://www.pbs.gov.au/medicine/item/1382R
54. Canadian Agency for Drugs and Technologies in Health. CEDAC Final Recommendation and Reasons for Recommendation, Ranibizumab. Mar, 2008 http://www.cadth.ca/media/cdr/complete/cdr_complete_Lucentis_March-27-2008.pdf
55. Saskatchewan Health, Appendix A of Exception Drug Status (EDS) Program. http://formulary.drugplan.health.gov.sk.ca/publications/APPENDIX%20A.pdf
56. 全民健康保險藥事小組第8屆第5次會議紀錄http://www.nhi.gov.tw/Resource/webdata/Attach_14079_2_第8屆第5次藥事小組會議紀錄.pdf
57. 全民健康保險藥事小組第8屆第9次會議紀錄http://www.nhi.gov.tw/Resource/webdata/Attach_14890_2_全民健康保險藥事小組第8屆第9次會議記錄0990111.pdf
58. 全民健康保險藥事小組第8屆第13次會議紀錄http://www.nhi.gov.tw/Resource/webdata/Attach_15476_2_全民健康保險藥事小組第8屆第13次會議紀錄.pdf
59. 全民健康保險藥事小組第8屆第17次會議紀錄http://www.nhi.gov.tw/Resource/webdata/Attach_15888_2_全民健康保險藥事小組第8屆第17次會議紀錄.pdf
60. Data refer to the year 2010. World Economic Outlook Database-April 2011, International Monetary Fund. http://www.imf.org/external/pubs/ft/weo/2011/01/weodata/index.aspx Monday, June 13, 2011.
61. OECD. Country Statistical Profiles 2010. OECD Health Data 2010 http://stats.oecd.org/Index.aspx?DatasetCode=CSP2010 Monday, June 13, 2011.
62. Chen SJ, Cheng CY, Peng KL, Li AF, Hsu WM, Liu JH, Chou P. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci. 2008;49(7):3126-33.
63. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640-2.
64. Arnold JJ, Sarks SH. Age-related macular degeneration. BMJ 2000;321:741-744
65. Zou HD, Zhang X, Xu X, Wang FH, Zhang SJ. Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai. Zhonghua Yan Ke Za Zhi. 2005;41(1):15-9.
66. WHO Scientific Group on the Prevention and Management of Osteoporosis (2000 : Geneva, Switzerland) (2003). "Prevention and management of osteoporosis : report of a WHO scientific group" (pdf). http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf. Retrieved 2010-01-26.
67. Yang NP, Deng CY, Chou YJ, et al. Estimated prevalence of osteoporosis from a nationwide health insurance database in Taiwan. Health Policy 2006;75:329-337.
68. 國際骨質疏鬆症基金會International Osteoporosis Foundation http://www.osteofound.org/press_centre/fact_sheet.html
69. Berry SD, Samelson EJ, Hannan MT, et al. Second hip fracture in older men and women. Arch Intern Med. 2007;167(18):1971-1976.
70. Black DM, Delmas PD, Eastell R, et al. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007:356:1809-22.
71. 全民健康保險藥事小組第8屆第18次會議紀錄http://www.nhi.gov.tw/Resource/webdata/Attach_15997_2_8-18會議紀錄-final.pdf
72. 國民健康局2007年台灣中老年身心社會生活狀況長期追蹤(第六次）調查
73. Black DM, Delmas PD, Eastell R, et al. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007:356:1809-22.
74. 游慧光(2004)，OECD國家與台灣醫療保健支出成長因素之探討，逢甲大學會計與財稅研究所碩士論文。
75. 陳昭姿，健保新藥管理趨勢，Dec 14, 2010
76. Frank R.G.,“Government Commitment and Regulation of Prescription Drugs” Health Affairs 2003;22(3):46-48.
77. 行政院衛生署中央健康保險局, 全民健康保險藥品給付規定http://www.nhi.gov.tw/Resource/webdata/15321_1_藥品給付規定條文.doc |
